Drug intelligence / Profile preview

disulfiram

Development stage
Approved
Lead developer
Xyzagen
Modality
Small Molecules
Administration
Oral
01

Overview

Disulfiram is a small molecule drug primarily used to support the treatment of chronic alcoholism by producing an acute sensitivity to ethanol. It acts as an irreversible inhibitor of the enzyme acetaldehyde dehydrogenase (ALDH), leading to accumulation of acetaldehyde when alcohol is consumed. This results in unpleasant physiological reactions such as flushing, tachycardia, hypotension, nausea, vomiting, and headache within minutes after alcohol intake. The deterrent effect helps discourage alcohol consumption[1][4][5]. Disulfiram does not reduce cravings for alcohol but relies on aversive conditioning. It is typically administered orally in tablet form and its effects can persist for up to two weeks after discontinuation due to slow elimination from the body[2][4].\nBeyond its approved use in alcohol dependence therapy, research has explored potential applications in cancer therapy (notably via inhibition of NPL4-p97 complex), parasitic infections, and latent HIV infection[1][5].

Brand names
Antabuse戒酒硫
Other names
双硫仑二硫化四乙基秋兰姆tetraethylthiuram disulfide
02

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)ALDH2 (Mitochondrial Aldehyde Dehydrogenase)

Beyond the preview

Go deeper on disulfiram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on disulfiram.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call